Design: cross sectional | ||||||
---|---|---|---|---|---|---|
Methylphenidate (mg/day) | Duration | n | Height (cm) | Height z-score | Controls | |
Beck et al, 197229 | Not stated No statistical analysis | Not stated | 30 | NS | Normal adolescents | |
Hechtman et al, 198430 | 20–50 No details given of analysis | ⩾3 years | 20 | NS | ADHD adults never treated | |
Normal adults | ||||||
Klein and Mannuzza, 198831 | 45 | 2.24 years | 61 boys | NS | Normal adolescents | |
Spencer et al, 1996,21 199822 | 38* | 4 years follow up | 25† men | NS | Normal adults | |
Uncertain proportion treated with stimulant | ||||||
Kramer et al, 200032 | 31.2 | 3 years | 97 men | NS | Adult family members | |
Normal adults | ||||||
Oettinger et al, 197733 | Dexamphetamine 16 mg/day | 4.5–16.2 years follow up | 25 men | NS | Normative data |
Design: longitudinal using multiple regression analysis | ||||||
---|---|---|---|---|---|---|
n, number of subjects; Duration, duration of treatment: average or range; NS, method used but did not show statistically significant evidence of attenuated growth. | ||||||
*Average dose of methylphenidate or equivalent. | ||||||
†Subgroup of individuals aged >18 years in a study principally of children. | ||||||
Loney et al, 198134 | 7% of variability of adolescent height predicted by treatment side effects | |||||
Kramer et al, 200032 | 4.4% of variability of adult height predicted by treatment side effects |